Idex Corporation · NYSE:IEX
Idex — Q3 2026 Earnings Presentation
21 slides from Idex's earnings presentation, Oct 28, 2026
Slide 1: Third Quarter 2026 Earnings Conference Call
Third Quarter 2026 Earnings Conference Call October 28, 2026
Slide 2: Cautionary Statement
Cautionary Statement Cautionary Statement Under the Private Securities Litigation Reform Act; Non-GAAP Measures This presentation contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may relate to, among other
Slide 3: IDEX 3Q26 Highlights
IDEX 3Q26 Highlights Advantaged markets in HST continue to power our growth Third quarter results exceeded our expectations, led by HST and FMT revenue and profitability Seeing a broadening of industrial strength across rapid- replenishment businesses All three segments expanded margins on volume le
Slide 4: Advantaged market focus driving higher growth
Advantaged market focus driving higher growth Represent over 1/3 of HST and ~20% of IDEX overall Data Center Semiconductor Space & Defense Water Power generation thermal Wafer positioning, instrument Optical and propulsion elements Advanced solutions for water management solutions and chip thermal m
Slide 5: Tuning Capabilities with Speed & Agility Boosts Organic Growth
Tuning Capabilities with Speed & Agility Boosts Organic Growth Core Capability Existing Application Tuned to New High-Growth Application (80) Impurity Removal Impurity Removal (Energy) (Semiconductor) Advanced metal MOTT filtration Designed filters to Tuned porosity control ensuring sub- withstand h
Slide 6: Industrial Growth Broadening; IDEX Weathering Inflationary Pressures
Industrial Growth Broadening; IDEX Weathering Inflationary Pressures FMT: DEMAND BROADENING IDEX: MANAGING INFLATION +4% 3Q26 organic sales growth* Positive price/cost on a dollar basis again in 3Q26 Ahead of the original plan Value supports pricing Orders and sales tracking ahead of initial forecas
Slide 7: 3Q26 Financial Performance
3Q26 Financial Performance ($ in millions excl. EPS) Sales Adj. EBITDA Margin* Adj. EPS* Free Cash Flow* +8% Organic* +50 bps +15% +14% YTD +6% YTD +50 bps YTD +14% YTD +12% $952 $2.33 $214 $879 27.8% 27.3% $2.03 $189 3Q25 3Q26 3Q25 3Q26 3Q25 3Q26 3Q25 3Q26 Quarter and YTD financial performance cons
Slide 8: 3Q26: Health & Science Technologies
3Q26: Health & Science Technologies ($ in millions) Orders Sales Adj. EBITDA Margin Performance Highlights +21% Organic* +13% Organic* +110 bps y/y • Advantaged market strength $468 $434 continues $390 $381 27.7% 28.8% • Adj EBITDA margin expansion driven primarily by volume leverage and positive mi
Slide 9: 3Q26: Fluid & Metering Technologies
3Q26: Fluid & Metering Technologies ($ in millions) Orders Sales Adj. EBITDA Margin Performance Highlights +11% Organic* +4% Organic* +20 bps y/y • Order strength is broadening 33.7% 33.9% $349 $317 $328 • Organic sales stronger in both $315 advantaged markets and base industrial businesses • Solid
Slide 10: 3Q26: Fire & Safety / Diversified Products
3Q26: Fire & Safety / Diversified Products ($ in millions) Orders Sales Adj. EBITDA Margin Performance Highlights +1% Organic* +6% Organic* +140 bps y/y • 3Q organic orders subdued mostly due to timing $176 $176 $182 $192 27.1% 28.5% • Organic sales growth driven by aerospace demand • Adj EBITDA mar
Slide 11: Capital Deployment
Capital Deployment Maintaining a balanced and returns-oriented approach IDEX Capital Deployment Framework Gross Leverage* Capital Deployment (YTD’25 vs. YTD’26) $455 $455 Maintain • Maintain investment grade credit rating 2.1x flexible 1.8x balance sheet • Gross leverage target < 2.0x $175 $228 Orga
Slide 12: 2026 Guidance Summary
2026 Guidance Summary FY26 FY26 Current Previous Organic* Sales Growth y/y 6.5% - 6.8% 5% - 6% Adjusted EBITDA Margin* 27.1% - 27.3% 27.0% - 27.3% Adjusted EPS* $8.91 - $8.96 $8.70 - $8.85 Other Modeling Items: FX Impact on Sales (a) ~0.5% ~0.5% Acquisition / Divestiture Impact on Sales ~0.5% ~0.5%
Slide 13: IDEX Value Drivers
IDEX Value Drivers Differentiated 8020 operating model drives full business potential through simplification, focused resourcing and streamlined execution Focused on continuously evolving our portfolio toward high-growth, advantaged markets with secular tailwinds Balanced allocator of capital with s
Slide 14: Non-GAAP Reconciliations
Non-GAAP Reconciliations *This presentation contains non-GAAP financial information whose reconciliations 14 are included in both this presentation and in our SEC filings.
Slide 15: Table 1: Reconciliations of the Change in Net Sales to Change in Organic Sales
Table 1: Reconciliations of the Change in Net Sales to Change in Organic Sales HST FMT FSDP IDEX Three Months Ended September 30, 2026 Change in net sales 14% 3% 5% 8% Less: Net impact from acquisitions/divestitures(1) 1% —% —% —% Impact from foreign currency(2) —% (1%) (1%) —% Change in organic sal
Slide 16: Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin
Table 2: Reconciliations of Reported-to-Adjusted Gross Profit and Gross Margin (dollars in millions) Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Gross profit $429.5 $390.6 $1,254.4 $1,151.7 Fair value inventory step-up charges — 0.6 — 0.6 Restructuring-relate
Slide 17: Table 3: Reconciliations of Reported-to-Adjusted Net Income and Diluted EPS
Table 3: Reconciliations of Reported-to-Adjusted Net Income Attributable to IDEX and Diluted EPS Attributable to IDEX (in millions, except per share amounts) *This presentation contains non-GAAP financial information whose reconciliations 17 are included in both this presentation and in our SEC fili
Slide 18: Footnote to Table 3
Footnote to Table 3 (1) Restructuring expenses and asset impairments and other restructuring-related charges consist of the following: Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 2026 2025 Restructuring expenses and asset impairments $3.4 $0.1 $13.6 $18.3 Less: Restruc
Slide 19: Table 4: Reconciliations of Net Income to Adjusted EBITDA
Table 4: Reconciliations of Net Income to Adjusted EBITDA (dollars in millions) (1) Accelerated depreciation of $0.7 million and $1.2 million for the three and nine months ended September 30, 2026, respectively, related to the anticipated closure of a facility in the HST segment, was included in Dep
Slide 20: Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow
Table 5: Reconciliations of Cash Flows from Operating Activities to Free Cash Flow (dollars in millions) *This presentation contains non-GAAP financial information whose reconciliations 20 are included in both this presentation and in our SEC filings.
Slide 21: Thank you.
Thank you. 21